HLB Therapeutics Co.,Ltd. (115450.KQ)
KRW 10680.0
(-2.11%)
KRW 10680.0
(-2.11%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 16.16 Billion KRW | 0.23% |
| 2022 | 15.5 Billion KRW | -1.3% |
| 2021 | 15.7 Billion KRW | -9.51% |
| 2020 | 17.35 Billion KRW | 2.54% |
| 2019 | 16.92 Billion KRW | 102.59% |
| 2018 | 8.35 Billion KRW | 22.42% |
| 2017 | 6.82 Billion KRW | -3.86% |
| 2016 | 7.09 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 4.15 Billion KRW | -10.01% |
| 2024 Q1 | 4.62 Billion KRW | 7.31% |
| 2023 FY | 15.53 Billion KRW | 0.23% |
| 2023 Q2 | 3.69 Billion KRW | 28.1% |
| 2023 Q3 | 5.03 Billion KRW | 36.45% |
| 2023 Q4 | 4.3 Billion KRW | -14.47% |
| 2023 Q1 | 2.88 Billion KRW | -48.71% |
| 2022 Q2 | 3.57 Billion KRW | 28.39% |
| 2022 FY | 15.5 Billion KRW | -1.3% |
| 2022 Q4 | 5.61 Billion KRW | -29.08% |
| 2022 Q3 | 7.92 Billion KRW | 121.7% |
| 2022 Q1 | 2.78 Billion KRW | -36.94% |
| 2021 Q4 | 4.41 Billion KRW | 24.83% |
| 2021 Q3 | 3.53 Billion KRW | 0.0% |
| 2021 FY | 15.7 Billion KRW | -9.51% |
| 2020 FY | 17.35 Billion KRW | 2.54% |
| 2019 FY | 16.92 Billion KRW | 102.59% |
| 2018 FY | 8.35 Billion KRW | 22.42% |
| 2017 FY | 6.82 Billion KRW | -3.86% |
| 2016 FY | 7.09 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| HLB Co., Ltd. | 109.98 Billion KRW | 85.301% |
| iNtRON Biotechnology, Inc. | 7.84 Billion KRW | -106.052% |
| BINEX Co., Ltd. | 55.67 Billion KRW | 70.963% |
| Bioneer Corporation | 204.55 Billion KRW | 92.097% |
| Anterogen.Co.,Ltd. | 7.74 Billion KRW | -108.864% |
| MEDIPOST Co., Ltd. | 65.31 Billion KRW | 75.248% |
| CrystalGenomics, Inc. | 32.36 Billion KRW | 50.057% |
| Helixmith Co., Ltd | 37.36 Billion KRW | 56.736% |
| Chabiotech Co.,Ltd. | 285.93 Billion KRW | 94.346% |
| Medy-Tox Inc. | 110.88 Billion KRW | 85.421% |
| Peptron, Inc. | 16.65 Billion KRW | 2.942% |
| Amicogen, Inc. | 52.82 Billion KRW | 69.395% |
| Genexine, Inc. | 41.62 Billion KRW | 61.165% |
| LegoChem Biosciences, Inc. | 98.61 Billion KRW | 83.607% |
| ALTEOGEN Inc. | 40.93 Billion KRW | 60.507% |
| PharmaResearch Co., Ltd. | 89.44 Billion KRW | 81.925% |
| SillaJen, Inc. | 5.11 Billion KRW | -216.231% |
| JETEMA, Co., Ltd. | 25.66 Billion KRW | 37.008% |
| OliX Pharmaceuticals,Inc | 35.24 Billion KRW | 54.137% |
| Genomictree Inc. | 16.26 Billion KRW | 0.605% |
| MedPacto, Inc. | 26.91 Billion KRW | 39.945% |
| D&D Pharmatech | 32.16 Billion KRW | 49.736% |
| EASY BIO,Inc. | 29.67 Billion KRW | 45.516% |
| GI Innovation, Inc. | 57.59 Billion KRW | 71.93% |